ALMSHealthcare · BiotechnologyALMS Stock Forecast: Alumis, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Alumis, Inc. hold a median 12-month price target of $39 — +40.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 6 Aug 2026 — in the lower half.
ALMS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Alumis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Alumis, Inc. — and when they’d sell — is the membership.
ALMS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALMS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +40.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | $25 |
| 19 May 2026 | Chardan Capital | Maintains | Buy | — |
| 19 May 2026 | Chardan Capital | Maintains | Buy | $38 → $40 |
| 15 May 2026 | Guggenheim | Maintains | Buy | — |
| 15 May 2026 | Guggenheim | Maintains | Buy | $32 → $34 |
| 15 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | $25 |
| 15 May 2026 | Wells Fargo | Maintains | Overweight | $49 → $51 |
| 15 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 30 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 Mar 2026 | Raymond James | Initiates | Strong Buy | — |
| 25 Feb 2026 | Stifel | Initiates | Buy | — |
| 21 Jan 2026 | Chardan Capital | Initiates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 7 Jan 2026 | Leerink Partners | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALMS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Alumis, Inc. (ALMS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.2×
- Price / sales
- 421.8×
- Price / book
- 6.2×
- EV / EBITDA
- −7.0×
Cheaper than 72% of US stocks
Cheaper than 2% of US stocks
Cheaper than 17% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- −90.0%
- Earnings growth (YoY)
- −90.0%
- Gross margin
- —
- Operating margin
- −5652.4%
- Net margin
- 0.0%
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −64.6%
- Return on assets
- −58.8%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ALMS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMS appears on the weeks it earns a place.
Frequently asked questions about ALMS stock
What is the ALMS stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Alumis, Inc. have a median 12-month price target of $39, with estimates ranging from $25 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALMS stock a buy right now?
Of the 10 analysts covering Alumis, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alumis, Inc. 40 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALMS?
As at 6 Aug 2026, Alumis, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will ALMS stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +40.3% from the last close, and Ticker Nerd's factor model ranks Alumis, Inc. 40 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALMS stock forecast for 2030?
No analyst covering Alumis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $55 over the next 12 months.
How has ALMS stock performed over the past year?
Alumis, Inc. returned +536.2% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alumis, Inc. do?
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines.
About Alumis, Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and expertise in immunology to advance a late-stage portfolio of next-generation treatments. Key pipeline assets include ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor targeting plaque psoriasis and systemic lupus erythematosus; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases; and programs addressing interferon regulatory factor 5 (IRF5) to correct immune dysfunction. Alumis Inc. focuses on optimizing patient outcomes across autoimmune disorders through innovative drug discovery, development, and potential commercialization efforts. Founded in 2021 and headquartered in South San Francisco, California, the company plays a significant role in the biotechnology sector by pioneering therapies that transform treatment paradigms for chronic immune conditions.
CEO Mr. Martin Babler Ph.D. · 225 employees · United States · https://www.alumis.com